Interpretation of <i>the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody</i>_Chinese Journal of Ocular Fundus Diseases

Authors：

Wang Xizi ¹ , Zheng Wenjie ² ,  Zhang Xiaomin ¹

1. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, China;
2. Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China;

Corresponding?author：

Zhang Xiaomin, Email: xzhang08@tmu.edu.cn

Keywords：

Anti-tumor necrosis factor-α monoclonal antibody; Non-infectious uveitis; Expert consensus; Interpretation

DOI：

10.3760/cma.j.cn511434-20240104-00005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

As a new treatment option after conventional corticosteroids and immunomodulatory drugs, biologics have been widely used in the clinical management of non-infectious uveitis in many countries due to their approved efficacy and safety. Anti-tumor necrosis factor-alpha monoclonal antibody is the most commonly used one. However, the guidance on its standardized application is lacking. The Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association compiled the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody. This evidence-based consensus is made according to the principle of consensus building and combines the clinical experience of the experts. Twelve recommendations are formatted on the application of Adalimumab and Infliximab. The interpretation of this consensus point will help improve the normative and effective application of anti-tumor necrosis factor-alpha monoclonal antibody in ophthalmologists, rheumatologists and immunologists.

Citation： Wang Xizi, Zheng Wenjie, Zhang Xiaomin. Interpretation of the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody. Chinese Journal of Ocular Fundus Diseases, 2024, 40(1): 20-26. doi: 10.3760/cma.j.cn511434-20240104-00005 Copy

1.	Valenzuela RA, Flores I, Urrutia B, et al. New pharmacological strategies for the treatment of non-infectious uveitis. A Minireview[J/OL]. Front Pharmacol, 2020, 11: 655[2020-05-08]. https://pubmed.ncbi.nlm.nih.gov/32508634/. DOI: 10.3389/fphar.2020.00655.
2.	Jiang Q, Li Z, Tao T, et al. TNF-α in uveitis: from bench to clinic[J/OL]. Front Pharmacol, 2021, 12: 740057[2021-11-02]. https://pubmed.ncbi.nlm.nih.gov/34795583/. DOI: 10.3389/fphar.2021.740057.
3.	Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics[J]. Int J Mol Sci, 2021, 22(5): 2719. DOI: 10.3390/ijms22052719.
4.	海峽兩岸醫藥衛生交流協會風濕免疫分會眼免疫學組. 抗腫瘤壞死因子-α單克隆抗體治療非感染性葡萄膜炎中國專家共識[J]. 中華眼底病雜志, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-00473.Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association. Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody[J]. Chin J Ocul Fundus Dis, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-00473.
5.	Tynj?l? P, Lindahl P, Honkanen V, et al. Infliximab and Etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2007, 66(4): 548-550. DOI: 10.1136/ard.2006.058248.
6.	Marotte H, Cimaz R. Etanercept-TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?[J]. Expert Opin Biol Ther, 2014, 14(5): 569-572. DOI: 10.1517/14712598.2014.896334.
7.	Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review[J/OL]. Front Med (Lausanne), 8: 695904[2021-09-10]. https://pubmed.ncbi.nlm.nih.gov/34568364/. DOI: 10.3389/fmed.2021.695904.
8.	Leone GM, Mangano K, Petralia MC, et al. Past, present and (foreseeable) future of biological anti-TNF alpha therapy[J]. J Clin Med, 2023, 12(4): 1630. DOI: 10.3390/jcm12041630.
9.	Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis[J]. N Engl J Med, 2016, 375(10): 932-943. DOI: 10.1056/NEJMoa1509852.
10.	Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL Ⅱ): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10050): 1183-1192. DOI: 10.1016/S0140-6736(16)31339-3.
11.	Yang P, Zhong Z, Du L, et al. Prevalence and clinical features of systemic diseases in Chinese patients with uveitis[J]. Br J Ophthalmol, 2021, 105(1): 75-82. DOI: 10.1136/bjophthalmol-2020-315960.
12.	李雁, 文小鳳, 魏來. 非感染性葡萄膜炎343例患者的分型、臨床表現及并發癥[J]. 眼科新進展, 2021, 41(7): 673-675. DOI: 10.13389/j.cnki.rao.2021.0139.Li Y, Wen XF, Wei L. Classification, clinical manifestations and complications of 343 non-infectious uveitis patients[J]. Rec Adv Ophthalmol, 2021, 41(7): 673-675. DOI: 10.13389/j.cnki.rao.2021.0139.
13.	Yang S, Tao T, Huang Z, et al. Adalimumab in Vogt-Koyanagi-Harada disease refractory to conventional therapy[J/OL]. Front Med (Lausanne), 2022, 8: 799427[2022-01-12]. https://pubmed.ncbi.nlm.nih.gov/35096888/. DOI: 10.3389/fmed.2021.799427.
14.	Nakai S, Takeuchi M, Usui Y, et al. Efficacy and safety of Adalimumab for exacerbation or relapse of ocular inflammation in patients with Vogt-Koyanagi-Harada disease: a multicenter study[J]. Ocul Immunol Inflamm, 2022, 24: 1-9. DOI: 10.1080/09273948.2022.2092007.
15.	Rahman N, Artiaga JCM, Bouras K, et al. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature[J]. J Ophthalmic Inflamm Infect, 2023, 13(1): 27. DOI: 10.1186/s12348-023-00333-6.
16.	Zhong Z, Dai L, Wu Q, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease[J]. Nat Commun, 2023, 14(1): 3768. DOI: 10.1038/s41467-023-39483-5.
17.	中華醫學會眼科學分會眼免疫學組, 中國醫師協會眼科醫師分會葡萄膜炎與免疫學組. 中國福格特-小柳-原田綜合征臨床診療專家共識(2023年)[J]. 中華眼科雜志, 2023, 59(7): 518-525. DOI: 10.3760/cma.j.cn112142-20230313-00098.Ocular Immunology Group, Ophthalmology Branch, Chinese Medical Association; Uveitis and Immunology Group, Ophthalmology Branch, Chinese Medical Doctor Association. Chinese expert consensus on the clinical diagnosis and treatment of Vogt-Koyanagi-Harada syndrome (2023)[J]. Chin J Ophthalmol, 2023, 59(7): 518-525. DOI: 10.3760/cma.j.cn112142-20230313-00098.
18.	Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis[J]. Expert Opin Biol Ther, 2019, 19(5): 477-490. DOI: 10.1080/14712598.2019.1595578.
19.	van der Houwen T, van Laar J. Beh?et's disease, and the role of TNF-α and TNF-α blockers[J]. Int J Mol Sci, 2020, 21(9): 3072. DOI: 10.3390/ijms21093072.
20.	Kone-Paut I, Barete S, Bodaghi B, et al. French recommendations for the management of Beh?et's disease[J]. Orphanet J Rare Dis, 2021, 16(Suppl 1): S352. DOI: 10.1186/s13023-020-01620-4.
21.	Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh?et's syndrome[J]. Ann Rheum Dis, 2018, 77(6): 808-818. DOI: 10.1136/annrheumdis-2018-213225.
22.	Karadag O, Bolek EC. Management of Behcet's syndrome[J]. Rheumatology (Oxford), 2020, 59(Suppl 3): Siii108-iii117. DOI: 10.1093/rheumatology/keaa086.
23.	Aboul Naga SH, Hassan LM, El Zanaty RT, et al. Beh?et uveitis: current practice and future perspectives[J/OL]. Front Med (Lausanne), 2022, 9: 968345[2022-09-07]. https://pubmed.ncbi.nlm.nih.gov/36160151/. DOI: 10.3389/fmed.2022.968345.
24.	Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Beh?et's disease following withdrawal of successful anti-tumor necrosis factor treatment[J]. Arthritis Rheumatol, 2017, 69(12): 2380-2385. DOI: 10.1002/art.40235.
25.	Sener H, Evereklioglu C, Horozoglu F, et al. Efficacy and safety of Adalimumab in patients with Beh?et uveitis: a systematic review and meta-analysis[J]. Ocul Immunol Inflamm, 2023, 10: 1-9. DOI: 10.1080/09273948.2022.2157288.
26.	Yang S, Huang Z, Hu Y, et al. The efficacy of Adalimumab as an initial treatment in patients with Beh?et's retinal vasculitis[J/OL]. Front Pharmacol, 2021, 12: 609148[2021-06-22]. https://pubmed.ncbi.nlm.nih.gov/34239438/. DOI: 10.3389/fphar.2021.609148.
27.	中華醫學會眼科學分會眼免疫學組, 中國醫師協會眼科醫師分會葡萄膜炎與免疫學組. 中國白塞綜合征性葡萄膜炎臨床診療專家共識(2023年)[J]. 中華眼科雜志, 2023, 59(8): 611-619. DOI: 10.3760/cma.j.cn112142-20230404-00137.Ocular Immunology Group, Ophthalmology Branch, Chinese Medical Association, Uveitis and Immunology Group, Ophthalmology Branch, Chinese Medical Doctor Association. Chinese expert consensus on the clinical diagnosis and treatment of Behcet′s uveitis (2023)[J]. Chin J Ophthalmol, 2023, 59(8): 611-619. DOI: 10.3760/cma.j.cn112142-20230404-00137.
28.	程衛東, 張美芬. 兒童非感染性葡萄膜炎藥物治療研究進展[J]. 中華眼科雜志, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.Chen WD, Zhang MF. Research progress of medication treatment of pediatric noninfectious uveitis[J]. Chin J Ophthalmol, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.
29.	中華醫學會兒科學分會免疫學組, 中國兒童風濕免疫病聯盟, 國家兒童健康與疾病臨床研究中心風濕免疫聯盟. 幼年特發性關節炎相關葡萄膜炎診療中國專家共識(2023)[J]. 協和醫學雜志, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.Immunology Group, Pediatrics Branch of Chinese Medical Association, China Children's Rheumatology Alliance, National Clinical Research Center for Child Health and Disease Rheumatology Alliance. Chinese expert consensus on juvenile idiopathic arthritis-associated uveitis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.
30.	Corredores J, Vofo B, Amer R. Uveitis in children: the role of biological agents in its management[J]. Biomedicines, 2023, 11(2): 629. DOI: 10.3390/biomedicines11020629.
31.	Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis[J/OL]. Acta Ophthalmol, 2022, 100(4): e994-e1001[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34532967/. DOI: 10.1111/aos.15012.
32.	Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors[J]. J Rheumatol, 2013, 40(8): 1394-1403. DOI: 10.3899/jrheum.121180.
33.	Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(4): 482-491. DOI: 10.1002/acr.23610.
34.	Solebo AL, Rahi JS, Dick AD, et al. Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK[J]. Br J Ophthalmol, 2020, 104(1): 11-16. DOI: 10.1136/bjophthalmol-2018-313789.
35.	Eurelings LEM, Missotten TOAR, van Velthoven MEJ, et al. Long-term follow-up of patients with uveitis treated with Adalimumab: response rates and reasons for discontinuation of therapy[J]. Am J Ophthalmol, 2022, 240: 194-204. DOI: 10.1016/j.ajo.2022.03.017.
36.	Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review[J]. Pharmacol Ther, 2008, 117(2): 244-279. DOI: 10.1016/j.pharmthera.2007.10.001.
37.	Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with Adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060.
38.	Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043-1046.
39.	Bellur S, McHarg M, Kongwattananon W, et al. Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis[J]. JAMA Ophthalmol, 2023, 141(2): 150-156. DOI: 10.1001/jamaophthalmol.2022.5584.
40.	Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies[J]. Ophthalmology, 2016, 123(12): 2618-2625. DOI: 10.1016/j.ophtha.2016.08.025.
41.	Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations[J]. Clin Rheumatol, 2018, 37(5): 1407-1411. DOI: 10.1007/s10067-018-4057-7.
42.	Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of Adalimumab therapy in refractory uveitis due to Beh?et's disease[J]. Ophthalmology, 2018, 125(9): 1444-1451. DOI: 10.1016/j.ophtha.2018.02.020.
43.	Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term follow-up and optimization of Infliximab in refractory uveitis due to Beh?et disease: national study of 103 white patients[J]. J Rheumatol, 2021, 48(5): 741-750. DOI: 10.3899/jrheum.200300.
44.	Salido Olivares M, Loza Santamaría E. Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: systematic review[J/OL]. Semin Arthritis Rheum, 2022, 52: 151944[2022-01-02]. https://pubmed.ncbi.nlm.nih.gov/35027247/. DOI: 10.1016/j.semarthrit.2021.11.010.
45.	Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives[J]. Lancet Gastroenterol Hepatol, 2022, 7(2): 171-185. DOI: 10.1016/S2468-1253(21)00223-5.
46.	Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis[J]. Clin Rheumatol, 2018, 37(2): 549-553. DOI: 10.1007/s10067-017-3890-4.
47.	Tambralli A, Beukelman T, Weiser P, et al. High doses of infliximab in the management of juvenile idiopathic arthritis[J]. J Rheumatol, 2013, 40(10): 1749-1755. DOI: 10.3899/jrheum.130133.
48.	Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease[J]. Ann Rheum Dis, 2013, 72(4): 517-524. DOI: 10.1136/annrheumdis-2011-201244.
49.	Namba K, Kaburaki T, Tsuruga H, et al. Long-term safety and effectiveness of Adalimumab in Japanese patients with noninfectious intermediate, posterior, or panuveitis: post-marketing surveillance of 251 patients[J]. Ophthalmol Ther, 2022, 11(3): 1147-1161. DOI: 10.1007/s40123-022-00493-z.
50.	Pham T, Bachelez H, Berthelot JM, et al. TNF alpha antagonist therapy and safety monitoring[J]. Joint Bone Spine, 2011, 78(Suppl 1): S15-185. DOI: 10.1016/S1297-319X(11)70001-X.
51.	譚雨亭, 侍效春, 劉曉清. 應用腫瘤壞死因子拮抗劑人群結核潛伏感染的檢測及預防性治療[J]. 協和醫學雜志, 2023, 14(2): 86-91. DOI: 10.12290/xhyxzz.20180406.Tan YT, Shi XC, Liu XQ. Testing and prophylaxis of latent tuberculosis infection in patients receiving tumor necrosis factor-α antagonists[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 86-91. DOI: 10.12290/xhyxzz.20180406.
52.	Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2): S10-20. DOI: 10.1016/j.cmi.2017.12.025.
53.	池瀅, 楊柳. 關注TNF-α抑制劑在葡萄膜炎治療中存在的感染和腫瘤發生及進展風險[J]. 中華實驗眼科雜志, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.Chi Y, Yang L. Pay attention to the risk of infection and tumor progression during application of TNF-α inhibitors in uveitis[J]. Chin J Pract Ophthalmol, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.
54.	腫瘤壞死因子拮抗劑應用中結核病預防與管理專家建議組. 腫瘤壞死因子拮抗劑應用中結核病預防與管理專家共識[J]. 中華風濕病學雜志, 2013, 17(8): 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002.Expert Recommendation Group on the Use of Tumor Necrosis Factor Antagonists in Tuberculosis Prevention and Management. Expert consensus on the use of tumor necrosis factor antagonists in tuberculosis prevention and management[J]. Chin J Rheumat, 2013, 17(8): 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002.
55.	王貴強, 段鐘平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版)[J]. 實用肝臟病雜志, 2020, 23(1): 9-32. DOI: 10.3969/j.issn.1672-5069.2020.01.044.Wang GQ, Duan ZP, Wang FS, et al. The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. J Prac Hepatol, 2020, 23(1): 9-32. DOI: 10.3969/j.issn.1672-5069.2020.01.044.
56.	中華醫學會皮膚性病學分會, 中國醫師協會皮膚科醫師分會, 中國中西醫結合學會皮膚性病專業委員會. 中國銀屑病生物治療專家共識(2019)[J]. 中華皮膚科雜志, 2019, 52(12): 863-871. DOI: 10.35541/cjd.20190892.Chinese Medical Association Dermatology and venereology Branch, Chinese Medical Doctor Association Dermatology Branch, Chinese Association of Integrated Traditional and Western Medicine Dermatology and venereology Professional Committee. Treatment of psoriasis with biological agents: a Chinese expert consensus statement (2019)[J]. Chin J Dermat, 2019, 52(12): 863-871. DOI: 10.35541/cjd.20190892.
57.	Gritsch D, Valencia-Sanchez C. Drug-related immune-mediated myelopathies[J/OL]. Front Neurol, 2022, 13: 1003270[2022-09-29]. https://pubmed.ncbi.nlm.nih.gov/36247761/. DOI: 10.3389/fneur.2022.1003270.
58.	李莉, 楊卓, 楊佳, 等. 基于FAERS的阿達木單抗相關不良事件風險信號挖掘[J]. 中國藥房, 2022, 33(16): 2006-2011. DOI: 10.6039/j.issn.1001-0408.2022.16.16.Li L, Yang Z, Yang J, et al. Risk signal mining of adverse event related to adalimumab based on FAERS[J]. China Pharmacy, 2022, 33(16): 2006-2011. DOI: 10.6039/j.issn.1001-0408.2022.16.16.

1. Valenzuela RA, Flores I, Urrutia B, et al. New pharmacological strategies for the treatment of non-infectious uveitis. A Minireview[J/OL]. Front Pharmacol, 2020, 11: 655[2020-05-08]. https://pubmed.ncbi.nlm.nih.gov/32508634/. DOI: 10.3389/fphar.2020.00655.
2. Jiang Q, Li Z, Tao T, et al. TNF-α in uveitis: from bench to clinic[J/OL]. Front Pharmacol, 2021, 12: 740057[2021-11-02]. https://pubmed.ncbi.nlm.nih.gov/34795583/. DOI: 10.3389/fphar.2021.740057.
3. Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics[J]. Int J Mol Sci, 2021, 22(5): 2719. DOI: 10.3390/ijms22052719.
4. 海峽兩岸醫藥衛生交流協會風濕免疫分會眼免疫學組. 抗腫瘤壞死因子-α單克隆抗體治療非感染性葡萄膜炎中國專家共識[J]. 中華眼底病雜志, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-00473.Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association. Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody[J]. Chin J Ocul Fundus Dis, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-00473.
5. Tynj?l? P, Lindahl P, Honkanen V, et al. Infliximab and Etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2007, 66(4): 548-550. DOI: 10.1136/ard.2006.058248.
6. Marotte H, Cimaz R. Etanercept-TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?[J]. Expert Opin Biol Ther, 2014, 14(5): 569-572. DOI: 10.1517/14712598.2014.896334.
7. Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review[J/OL]. Front Med (Lausanne), 8: 695904[2021-09-10]. https://pubmed.ncbi.nlm.nih.gov/34568364/. DOI: 10.3389/fmed.2021.695904.
8. Leone GM, Mangano K, Petralia MC, et al. Past, present and (foreseeable) future of biological anti-TNF alpha therapy[J]. J Clin Med, 2023, 12(4): 1630. DOI: 10.3390/jcm12041630.
9. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis[J]. N Engl J Med, 2016, 375(10): 932-943. DOI: 10.1056/NEJMoa1509852.
10. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL Ⅱ): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10050): 1183-1192. DOI: 10.1016/S0140-6736(16)31339-3.
11. Yang P, Zhong Z, Du L, et al. Prevalence and clinical features of systemic diseases in Chinese patients with uveitis[J]. Br J Ophthalmol, 2021, 105(1): 75-82. DOI: 10.1136/bjophthalmol-2020-315960.
12. 李雁, 文小鳳, 魏來. 非感染性葡萄膜炎343例患者的分型、臨床表現及并發癥[J]. 眼科新進展, 2021, 41(7): 673-675. DOI: 10.13389/j.cnki.rao.2021.0139.Li Y, Wen XF, Wei L. Classification, clinical manifestations and complications of 343 non-infectious uveitis patients[J]. Rec Adv Ophthalmol, 2021, 41(7): 673-675. DOI: 10.13389/j.cnki.rao.2021.0139.
13. Yang S, Tao T, Huang Z, et al. Adalimumab in Vogt-Koyanagi-Harada disease refractory to conventional therapy[J/OL]. Front Med (Lausanne), 2022, 8: 799427[2022-01-12]. https://pubmed.ncbi.nlm.nih.gov/35096888/. DOI: 10.3389/fmed.2021.799427.
14. Nakai S, Takeuchi M, Usui Y, et al. Efficacy and safety of Adalimumab for exacerbation or relapse of ocular inflammation in patients with Vogt-Koyanagi-Harada disease: a multicenter study[J]. Ocul Immunol Inflamm, 2022, 24: 1-9. DOI: 10.1080/09273948.2022.2092007.
15. Rahman N, Artiaga JCM, Bouras K, et al. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature[J]. J Ophthalmic Inflamm Infect, 2023, 13(1): 27. DOI: 10.1186/s12348-023-00333-6.
16. Zhong Z, Dai L, Wu Q, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease[J]. Nat Commun, 2023, 14(1): 3768. DOI: 10.1038/s41467-023-39483-5.
17. 中華醫學會眼科學分會眼免疫學組, 中國醫師協會眼科醫師分會葡萄膜炎與免疫學組. 中國福格特-小柳-原田綜合征臨床診療專家共識(2023年)[J]. 中華眼科雜志, 2023, 59(7): 518-525. DOI: 10.3760/cma.j.cn112142-20230313-00098.Ocular Immunology Group, Ophthalmology Branch, Chinese Medical Association; Uveitis and Immunology Group, Ophthalmology Branch, Chinese Medical Doctor Association. Chinese expert consensus on the clinical diagnosis and treatment of Vogt-Koyanagi-Harada syndrome (2023)[J]. Chin J Ophthalmol, 2023, 59(7): 518-525. DOI: 10.3760/cma.j.cn112142-20230313-00098.
18. Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis[J]. Expert Opin Biol Ther, 2019, 19(5): 477-490. DOI: 10.1080/14712598.2019.1595578.
19. van der Houwen T, van Laar J. Beh?et's disease, and the role of TNF-α and TNF-α blockers[J]. Int J Mol Sci, 2020, 21(9): 3072. DOI: 10.3390/ijms21093072.
20. Kone-Paut I, Barete S, Bodaghi B, et al. French recommendations for the management of Beh?et's disease[J]. Orphanet J Rare Dis, 2021, 16(Suppl 1): S352. DOI: 10.1186/s13023-020-01620-4.
21. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh?et's syndrome[J]. Ann Rheum Dis, 2018, 77(6): 808-818. DOI: 10.1136/annrheumdis-2018-213225.
22. Karadag O, Bolek EC. Management of Behcet's syndrome[J]. Rheumatology (Oxford), 2020, 59(Suppl 3): Siii108-iii117. DOI: 10.1093/rheumatology/keaa086.
23. Aboul Naga SH, Hassan LM, El Zanaty RT, et al. Beh?et uveitis: current practice and future perspectives[J/OL]. Front Med (Lausanne), 2022, 9: 968345[2022-09-07]. https://pubmed.ncbi.nlm.nih.gov/36160151/. DOI: 10.3389/fmed.2022.968345.
24. Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Beh?et's disease following withdrawal of successful anti-tumor necrosis factor treatment[J]. Arthritis Rheumatol, 2017, 69(12): 2380-2385. DOI: 10.1002/art.40235.
25. Sener H, Evereklioglu C, Horozoglu F, et al. Efficacy and safety of Adalimumab in patients with Beh?et uveitis: a systematic review and meta-analysis[J]. Ocul Immunol Inflamm, 2023, 10: 1-9. DOI: 10.1080/09273948.2022.2157288.
26. Yang S, Huang Z, Hu Y, et al. The efficacy of Adalimumab as an initial treatment in patients with Beh?et's retinal vasculitis[J/OL]. Front Pharmacol, 2021, 12: 609148[2021-06-22]. https://pubmed.ncbi.nlm.nih.gov/34239438/. DOI: 10.3389/fphar.2021.609148.
27. 中華醫學會眼科學分會眼免疫學組, 中國醫師協會眼科醫師分會葡萄膜炎與免疫學組. 中國白塞綜合征性葡萄膜炎臨床診療專家共識(2023年)[J]. 中華眼科雜志, 2023, 59(8): 611-619. DOI: 10.3760/cma.j.cn112142-20230404-00137.Ocular Immunology Group, Ophthalmology Branch, Chinese Medical Association, Uveitis and Immunology Group, Ophthalmology Branch, Chinese Medical Doctor Association. Chinese expert consensus on the clinical diagnosis and treatment of Behcet′s uveitis (2023)[J]. Chin J Ophthalmol, 2023, 59(8): 611-619. DOI: 10.3760/cma.j.cn112142-20230404-00137.
28. 程衛東, 張美芬. 兒童非感染性葡萄膜炎藥物治療研究進展[J]. 中華眼科雜志, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.Chen WD, Zhang MF. Research progress of medication treatment of pediatric noninfectious uveitis[J]. Chin J Ophthalmol, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.
29. 中華醫學會兒科學分會免疫學組, 中國兒童風濕免疫病聯盟, 國家兒童健康與疾病臨床研究中心風濕免疫聯盟. 幼年特發性關節炎相關葡萄膜炎診療中國專家共識(2023)[J]. 協和醫學雜志, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.Immunology Group, Pediatrics Branch of Chinese Medical Association, China Children's Rheumatology Alliance, National Clinical Research Center for Child Health and Disease Rheumatology Alliance. Chinese expert consensus on juvenile idiopathic arthritis-associated uveitis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.
30. Corredores J, Vofo B, Amer R. Uveitis in children: the role of biological agents in its management[J]. Biomedicines, 2023, 11(2): 629. DOI: 10.3390/biomedicines11020629.
31. Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis[J/OL]. Acta Ophthalmol, 2022, 100(4): e994-e1001[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34532967/. DOI: 10.1111/aos.15012.
32. Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors[J]. J Rheumatol, 2013, 40(8): 1394-1403. DOI: 10.3899/jrheum.121180.
33. Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(4): 482-491. DOI: 10.1002/acr.23610.
34. Solebo AL, Rahi JS, Dick AD, et al. Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK[J]. Br J Ophthalmol, 2020, 104(1): 11-16. DOI: 10.1136/bjophthalmol-2018-313789.
35. Eurelings LEM, Missotten TOAR, van Velthoven MEJ, et al. Long-term follow-up of patients with uveitis treated with Adalimumab: response rates and reasons for discontinuation of therapy[J]. Am J Ophthalmol, 2022, 240: 194-204. DOI: 10.1016/j.ajo.2022.03.017.
36. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review[J]. Pharmacol Ther, 2008, 117(2): 244-279. DOI: 10.1016/j.pharmthera.2007.10.001.
37. Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with Adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060.
38. Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043-1046.
39. Bellur S, McHarg M, Kongwattananon W, et al. Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis[J]. JAMA Ophthalmol, 2023, 141(2): 150-156. DOI: 10.1001/jamaophthalmol.2022.5584.
40. Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies[J]. Ophthalmology, 2016, 123(12): 2618-2625. DOI: 10.1016/j.ophtha.2016.08.025.
41. Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations[J]. Clin Rheumatol, 2018, 37(5): 1407-1411. DOI: 10.1007/s10067-018-4057-7.
42. Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of Adalimumab therapy in refractory uveitis due to Beh?et's disease[J]. Ophthalmology, 2018, 125(9): 1444-1451. DOI: 10.1016/j.ophtha.2018.02.020.
43. Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term follow-up and optimization of Infliximab in refractory uveitis due to Beh?et disease: national study of 103 white patients[J]. J Rheumatol, 2021, 48(5): 741-750. DOI: 10.3899/jrheum.200300.
44. Salido Olivares M, Loza Santamaría E. Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: systematic review[J/OL]. Semin Arthritis Rheum, 2022, 52: 151944[2022-01-02]. https://pubmed.ncbi.nlm.nih.gov/35027247/. DOI: 10.1016/j.semarthrit.2021.11.010.
45. Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives[J]. Lancet Gastroenterol Hepatol, 2022, 7(2): 171-185. DOI: 10.1016/S2468-1253(21)00223-5.
46. Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis[J]. Clin Rheumatol, 2018, 37(2): 549-553. DOI: 10.1007/s10067-017-3890-4.
47. Tambralli A, Beukelman T, Weiser P, et al. High doses of infliximab in the management of juvenile idiopathic arthritis[J]. J Rheumatol, 2013, 40(10): 1749-1755. DOI: 10.3899/jrheum.130133.
48. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease[J]. Ann Rheum Dis, 2013, 72(4): 517-524. DOI: 10.1136/annrheumdis-2011-201244.
49. Namba K, Kaburaki T, Tsuruga H, et al. Long-term safety and effectiveness of Adalimumab in Japanese patients with noninfectious intermediate, posterior, or panuveitis: post-marketing surveillance of 251 patients[J]. Ophthalmol Ther, 2022, 11(3): 1147-1161. DOI: 10.1007/s40123-022-00493-z.
50. Pham T, Bachelez H, Berthelot JM, et al. TNF alpha antagonist therapy and safety monitoring[J]. Joint Bone Spine, 2011, 78(Suppl 1): S15-185. DOI: 10.1016/S1297-319X(11)70001-X.
51. 譚雨亭, 侍效春, 劉曉清. 應用腫瘤壞死因子拮抗劑人群結核潛伏感染的檢測及預防性治療[J]. 協和醫學雜志, 2023, 14(2): 86-91. DOI: 10.12290/xhyxzz.20180406.Tan YT, Shi XC, Liu XQ. Testing and prophylaxis of latent tuberculosis infection in patients receiving tumor necrosis factor-α antagonists[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 86-91. DOI: 10.12290/xhyxzz.20180406.
52. Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2): S10-20. DOI: 10.1016/j.cmi.2017.12.025.
53. 池瀅, 楊柳. 關注TNF-α抑制劑在葡萄膜炎治療中存在的感染和腫瘤發生及進展風險[J]. 中華實驗眼科雜志, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.Chi Y, Yang L. Pay attention to the risk of infection and tumor progression during application of TNF-α inhibitors in uveitis[J]. Chin J Pract Ophthalmol, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.
54. 腫瘤壞死因子拮抗劑應用中結核病預防與管理專家建議組. 腫瘤壞死因子拮抗劑應用中結核病預防與管理專家共識[J]. 中華風濕病學雜志, 2013, 17(8): 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002.Expert Recommendation Group on the Use of Tumor Necrosis Factor Antagonists in Tuberculosis Prevention and Management. Expert consensus on the use of tumor necrosis factor antagonists in tuberculosis prevention and management[J]. Chin J Rheumat, 2013, 17(8): 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002.
55. 王貴強, 段鐘平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版)[J]. 實用肝臟病雜志, 2020, 23(1): 9-32. DOI: 10.3969/j.issn.1672-5069.2020.01.044.Wang GQ, Duan ZP, Wang FS, et al. The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. J Prac Hepatol, 2020, 23(1): 9-32. DOI: 10.3969/j.issn.1672-5069.2020.01.044.
56. 中華醫學會皮膚性病學分會, 中國醫師協會皮膚科醫師分會, 中國中西醫結合學會皮膚性病專業委員會. 中國銀屑病生物治療專家共識(2019)[J]. 中華皮膚科雜志, 2019, 52(12): 863-871. DOI: 10.35541/cjd.20190892.Chinese Medical Association Dermatology and venereology Branch, Chinese Medical Doctor Association Dermatology Branch, Chinese Association of Integrated Traditional and Western Medicine Dermatology and venereology Professional Committee. Treatment of psoriasis with biological agents: a Chinese expert consensus statement (2019)[J]. Chin J Dermat, 2019, 52(12): 863-871. DOI: 10.35541/cjd.20190892.
57. Gritsch D, Valencia-Sanchez C. Drug-related immune-mediated myelopathies[J/OL]. Front Neurol, 2022, 13: 1003270[2022-09-29]. https://pubmed.ncbi.nlm.nih.gov/36247761/. DOI: 10.3389/fneur.2022.1003270.
58. 李莉, 楊卓, 楊佳, 等. 基于FAERS的阿達木單抗相關不良事件風險信號挖掘[J]. 中國藥房, 2022, 33(16): 2006-2011. DOI: 10.6039/j.issn.1001-0408.2022.16.16.Li L, Yang Z, Yang J, et al. Risk signal mining of adverse event related to adalimumab based on FAERS[J]. China Pharmacy, 2022, 33(16): 2006-2011. DOI: 10.6039/j.issn.1001-0408.2022.16.16.

Chinese Journal of Ocular Fundus Diseases

Interpretation of the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content